Percutaneous coronary intervention in nonagenarians with acute myocardial infarction: a 15-year population-based

Giancarlo Marenzi1, Nicola Cosentino2, Daniela Mele2

  • 1Centro Cardiologico Monzino IRCCS, Via Parea 4, Milan, 20138, Italy. giancarlo.marenzi@ccfm.it.

Scientific Reports
|January 8, 2026
PubMed

Insights

Percutaneous coronary intervention (PCI) significantly reduces mortality and rehospitalization for acute myocardial infarction (AMI) in patients over 90 years old. These benefits persist regardless of patient comorbidities, supporting PCI use in this elderly population.

Area of Science:

  • Cardiology
  • Geriatric Medicine
  • Interventional Cardiology

Background:

  • Percutaneous coronary intervention (PCI) use in very elderly patients (over 90 years) with acute myocardial infarction (AMI) is debated due to limited evidence and high rates of multimorbidity.
  • Optimal treatment strategies for AMI in this specific demographic remain unclear.

Purpose of the Study:

  • To evaluate the impact and outcomes of PCI in patients aged 90 years and older diagnosed with AMI.
  • To assess the association of PCI with in-hospital mortality, one-year mortality, and rehospitalization rates in this vulnerable population.

Main Methods:

  • Retrospective analysis of the Lombardy Health Database (Italy) including AMI patients hospitalized between 2003 and 2018.
  • Comparison of outcomes between patients who underwent PCI and those who did not, utilizing adjusted risk analyses and propensity score matching.
  • Subgroup analysis for ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI) patients.

Main Results:

  • PCI was performed in 12% of 15,954 AMI patients (median age 92).
  • PCI-treated patients showed lower in-hospital mortality (15% vs. 23%) and one-year mortality (37% vs. 58%).
  • Rehospitalization rates for acute heart failure or AMI were also reduced in PCI recipients (16% vs. 21%), irrespective of comorbidities.

Conclusions:

  • PCI is associated with significantly improved survival and reduced rehospitalization in patients over 90 years with AMI.
  • The benefits of PCI were observed consistently across STEMI and NSTEMI subgroups and were independent of comorbidities.
  • Findings support the consideration of PCI in very elderly AMI patients, challenging previous debates on its utility in this age group.

Related Concept Videos

Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
207
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
214
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
183
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
785
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
223
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
580